MAPT and Alzheimer disease: Both preclinical and clinical studies had proved that 18F-APN-1607 highly selectively combined with the pathological tau of AD and could visualize the spatial distribution of tau deposition in AD (Ni et al., 2018; Hsu et al., 2020; Weng et al., 2020; Tagai et al., 2021).